T-cell CD38 expression in B-chronic lymphocytic leukaemia

Hematological Oncology

Volumn 27, Issue 2, 2009, Pages 82-89

  Abousamra, Nashwa Khayrat ^a   El Din, Manal Salah ^a   Azmy, Emad ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

B CLL; CD38; Prognostic factors; T cell

Indexed keywords

CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CANCER SURVIVAL; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD38; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 66949154050     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.877     Document Type: Article

References (37)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-1057.
2. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia. Lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003; 21: 841-894.
3. Rai KR, Sawitsky A, Cronckite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
4. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
5. Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol 2000; 27: 587-597.
6. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42-59.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV (H) genes are associated with a more aggressive form lymphocytic leukemia. Blood 1999; 94: 1848-1854.
8. Hamblin TJ. Prognostic markers in chronic lymphocytic leukemia. Best pract Res clin Haematol 2007; 20: 455-468.
9. Damle RN, Wasil T, Fais F, et al. IgV gene mutation status and CD38 expression as a novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
10. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
11. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98: 181-186.
12. D'Arena G, Musto P, Cascavilla N, et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2001; 42: 109-114.
13. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
14. Kröber A, Seiler T, Benner A, et al. VH mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
15. Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17 p deletion are important prognostic factors in chronic lymphocytic leukemia. Br J Haematol 2002; 116: 142-150.
16. Motta M, Rassenti L, Shelvin BJ, et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1788-1793.
17. Scriveners S, Goddard RV, Kaminski ER, Prentice AG. Abnormal T-cell function in B-cell chronic lymphocytic leukemia. Leuk lymphoma 2003; 44: 383-389.
18. Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K. Human D38: a glycoprotein in search of a function. Immunol Today 1994; 15: 95-97.
19. Funaro A, Spagnoli GC, Ausiello CM, et al. Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol 1990; 145: 2390-2396.
20. Tinhofer I, Rubenzer G, Holler C, et al. Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. Blood 2006; 108: 2950-2956.
21. Höffkes HG, Schmidtke G, Uppenkamp M, Schmücker U. Multiparametric immunophenotyping of B cells in peripheral blood of healthy adults by flowcytometry. Clin Diagn Lab Immunol 1996; 3: 30-36.
22. Cheson BD, Bennett JM, Grever M, et al. National cancer institute sponsored working group guideline for chronic lymphocytic leukemia: revised guideline for diagnosis and treatment. Blood 1996; 87: 4990-4997.
23. Kokhaei P, Palme M, Mellstedt H, Choudhury A. Biology and treatment of chronic lymphocytic leukemia. Ann oncol 2005; 16 (Suppl 2): ii113-ii 123.
24. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
25. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006; 4: 683-690.
26. Armitage P, Berry G. Statistical Methods in Medical Research (2nd edn). Blackwell Scientific Publications: Oxford, England, 1987.
27. Phiel KL, Henderson RA, Adelman SJ, Elloso MM. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett 2005; 97: 107-113.
28. Benten WP, Becker A, Schmitt-Wrede HP,Wunderlich F. Developmental regulation of intra-cellular and surface androgen receptors in T cells. Steroids 2002; 67: 925-931.
29. Kohen F, Abel L, Sharp A, et al. Estrogen-receptors expression and function in thymocytes in relation to gender and age. Dev Immunol 1998; 5: 277-285.
30. CLL Trialists' Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst 1999; 91: 861-868.
31. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: Integrating molecular biologic insight into clinical practice for patients with CLL. Blood 2004; 103: 1202-1210.
32. Hamblin T, Orchard JA, Davies ZA, et al. In chronic lymphocytic leukemia females survive for longer than males even in patients with unmutated immunoglobulin genes [abstract]. Blood 2004; 104: 9a. Abstract 16.
33. Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk lymphoma 2006; 47: 1477-1480.
34. Tinhofer I, Rubenzer G, Holler C, Stoecher M, Egle A, Greil R. Improved risk assessment in B-cell chronic lymphocytic leukemia based on sex-specific molecular profiling [abstract]. J Clin Oncol 2007; 25: abstract 7090.
35. Galal OM. The nutrition transition in Egypt: obesity, undernutrition and the food consumption context. Public Health Nutr 2002; 5: 141-148.
36. McTiernan A, Rajan KB, Tworoger SS, et al. Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 2003; 15: 1961-1966.
37. Mahabir S, Baer DJ, Johnson LL, et al. Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2502-2507.